Parsey Merdad 4
4 · GILEAD SCIENCES, INC. · Filed Nov 29, 2024
Insider Transaction Report
Form 4
Parsey Merdad
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2024-11-27$65.38/sh+88,119$5,761,220→ 245,012 total - Sale
Common Stock
2024-11-27$92.00/sh−88,119$8,106,948→ 99,599 total - Sale
Common Stock
2024-11-27$92.00/sh−10,399$956,708→ 80,801 total - Sale
Common Stock
2024-11-27$91.80/sh−5,200$477,381→ 94,399 total - Exercise/Conversion
Non-qualified Stock Option (Right to Buy)
2024-11-27−57,294→ 64,376 totalExercise: $57.92Exp: 2032-03-10→ Common Stock (57,294 underlying) - Exercise/Conversion
Non-qualified Stock Option (Right to Buy)
2024-11-27−88,119→ 196 totalExercise: $65.38Exp: 2029-11-10→ Common Stock (88,119 underlying) - Sale
Common Stock
2024-11-27$91.80/sh−3,199$293,679→ 91,200 total - Exercise/Conversion
Common Stock
2024-11-27$57.92/sh+57,294$3,318,468→ 156,893 total - Sale
Common Stock
2024-11-27$91.79/sh−57,294$5,259,297→ 187,718 total
Footnotes (4)
- [F1]Sale prices reported for the transactions reported here range from $91.451 to $92.095. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
- [F2]Sale prices reported for the transactions reported here range from $91.458 to $92.04. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
- [F3]Sale prices reported for the transactions reported here range from $91.451 to $92.035. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
- [F4]The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.